Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PPID | Q08752 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473169 | 1.00 | PRMT6 (0.42) | PRMT6HTR7DHODHEPHX2PPID | |
| SCHEMBL6473173 | 0.93 | PRMT6 (0.41) | PRMT6HTR7DHODHEPHX2PPID | |
| SCHEMBL6531486 | 0.84 | PPID (0.37) | DHODHEPHX2PPIDSYKFFAR1 | |
| SCHEMBL6531479 | 0.84 | PPID (0.37) | DHODHEPHX2PPIDSYKFFAR1 | |
| SCHEMBL6473082 | 0.82 | EPHX2 (0.38) | EPHX2PPID | |
| SCHEMBL6473073 | 0.82 | EPHX2 (0.38) | EPHX2PPID | |
| SCHEMBL6473080 | 0.79 | AOC3 (0.41) | — | |
| SCHEMBL6184148 | 0.78 | PRMT6 (0.49) | PRMT6HTR7EPHX2BCL2FFAR1 | |
| SCHEMBL6184145 | 0.78 | PRMT6 (0.49) | PRMT6HTR7EPHX2BCL2FFAR1 | |
| SCHEMBL6531485 | 0.78 | PPID (0.36) | DHODHEPHX2PPIDNR1H4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | PRMT6 4002/4885HTR7 1352/4885DHODH 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.